Blue Sail Medical (002382.SZ): Two Stent Products Shortlisted in National Coronary Stent Volume-Based Procurement with Significantly Higher Bids Than First Round

Intelligent Finance APP, Bluesail Medical (002382.SZ) announced that on November 29, 2022, its wholly-owned subsidiary, Jw Medical Systems Limited ("JWMS"), participated in the information disclosure meeting for the continuation procurement following the expiration of the national coronary stent centralized volume-based procurement agreement. Two products are proposed to have won bids in this centralized volume-based procurement. The names of the proposed winning products are: Drug-Coated Stent System (Rapamycin) (Xinyue).^®Biodegradable Coating Drug-Eluting Coronary Stent, EXCROSSAL), Cobalt-Chromium Alloy Biodegradable Coating Sirolimus-Eluting Coronary Stent System (Xinkuo)^®Biodegradable Coating Drug-Eluting Coronary Stent, EXPANSAL).

It is reported that this centralized procurement is the second coronary stent bulk procurement organized by the state. Compared with the first procurement's winning bid price of 469 yuan per unit, the company's proposed winning bid price this time has significantly increased to 824 yuan per unit and 845 yuan per unit. The company's EXCROSSAL stent has become the product with the largest price increase among the products that won the bid in the first procurement.